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Similar turnover and shedding of the cellular prion protein in
primary lymphoid and neuronal cells
Abstract
The cellular prion protein (PrP(C)) is essential for pathogenesis and transmission of prion diseases.
Although prion replication in the brain is accompanied by neurodegeneration, prions multiply efficiently
in the lymphoreticular system without any detectable pathology. We have used pulse-chase metabolic
radiolabeling experiments to investigate the turnover and processing of PrP(C) in primary cell cultures
derived from lymphoid and nervous tissues. Similar kinetics of PrP(C) degradation were observed in
these tissues. This indicates that the differences between these two organs with respect to their capacity
to replicate prions is not due to differences in the turnover of PrP(C). Substantial amounts of a soluble
form of PrP that lacks the glycolipid anchor appeared in the medium of splenocytes and cerebellar
granule cells. Soluble PrP was detected in murine and human serum, suggesting that it might be of
physiological relevance.
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The cellular prion protein (PrPC) is essential for
pathogenesis and transmission of prion diseases. Al-
though prion replication in the brain is accompanied by
neurodegeneration, prions multiply efficiently in the
lymphoreticular system without any detectable pathol-
ogy. We have used pulse-chase metabolic radiolabeling
experiments to investigate the turnover and processing
of PrPC in primary cell cultures derived from lymphoid
and nervous tissues. Similar kinetics of PrPC degrada-
tion were observed in these tissues. This indicates that
the differences between these two organs with respect
to their capacity to replicate prions is not due to differ-
ences in the turnover of PrPC. Substantial amounts of a
soluble form of PrP that lacks the glycolipid anchor
appeared in the medium of splenocytes and cerebellar
granule cells. Soluble PrP was detected in murine and
human serum, suggesting that it might be of physiolog-
ical relevance.
Transmissible spongiform encephalopathies or prion disease
are fatal neurological disorders that share the same basic path-
ogenic mechanisms, involving the structural conversion of the
normal host prion protein (PrPC)1 into a protease-resistant
form (PrPSc) (reviewed in Ref. 1). PrPSc is thought to be con-
gruent with the infectious agent. The pathologic hallmarks of
prion diseases are confined to the nervous system, where pri-
ons replicate efficiently. However in several mouse models of
transmissible spongiform encephalopathies and in natural
scrapie, as well as in variant Creutzfeldt-Jakob disease, prions
replicate in lymphoid tissues long before infection spreads to
the brain (2).
Some of the cell types involved in prion replication in nerv-
ous and lymphoid tissues have been elucidated. Using PrP
knockout mice with ectopic, cell-restricted expression of PrPC,
it has been shown that in the brain, neurons (3) and astrocytes
(4) are capable of propagating prions. In the lymphoreticular
system, replication of some prion strains may be dependent on
follicular dendritic cells (5), although this may not be a univer-
sal phenomenon (6, 7).
Little is known about the efficiency with which nervous and
lymphoid cells replicate prions. It is conceivable that the early
rise of infectivity titers in the lymphoreticular system (8) is due
to a faster replication of prions in some cell types of the lym-
phoreticular system. It is also possible that increased turnover
rates of PrPC could result in an increased rate of conversion of
PrPC into PrPSc.
Studies with a neuroblastoma cell line showed that PrPC is
transported to the cell surface within 1 h of its synthesis and is
degraded with a half-life of 3–6 h (9, 10). A small portion of
PrPC (10–30% of the cell surface pool) is shed into the medium
by cultured cells (9–13). The released PrPC may be produced by
cleavage within the GPI region (13), or it may be shed into the
medium after loss of its GPI anchor (12). Soluble forms of PrPC
have been identified not only in the medium of cultured cells
but also in human cerebrospinal fluid (14) and have been re-
leased from human platelets (15).
Although these studies have shed some light on the cellular
pathways of PrP biosynthesis and metabolism, they may not
reflect completely the in vivo situation, and they do not address
the importance of PrP expression and turnover in the lym-
phoreticular system (16–18), where prions replicate efficiently
throughout the disease (8, 19).
In this report, we used primary splenocyte cultures to study
the turnover of PrPC in the lymphoreticular system and com-
pared it with the turnover of PrPC in primary cerebellar gran-
ule cell cultures. Both cell types showed similar turnover rates
of PrPC. We found that PrPC turnover was significantly faster
in primary cells than in cell lines of related origin. A substan-
tial level of PrP was shed into the medium after loss of the GPI
anchor. Shedding of PrP was found to be increased 3-fold in the
presence of serum, suggesting that serum phospholipases
might play a role in the shedding process.
MATERIALS AND METHODS
Primary Neuron Cultures—Cultures enriched in granule neurons
were obtained from cerebella of 7-day-old mice as described previously
(39). Briefly, cells were dissociated from freshly dissected cerebella by
mechanical disruption in the presence of trypsin and DNase I. Cells
were plated in Dulbecco’s modified Eagle’s medium (Life Technologies)
supplemented with 10% fetal bovine serum, L-glutamine (Life Technol-
ogies), penicillin/streptomycin, and 25 mM KCl at a density of 3 
105/cm2 (2.5  106/35-mm dish).
CPs2 Cells—A PrP expression vector containing murine PrP driven
by the CMV promoter was constructed by inserting the murine “half-
genomic” PrP sequence as a blunted BamHI-SalI fragment excised from
the plasmid pPrP-5HG SalI (19) into the SalI-BglII restricted and
blunted pAd-CMV-lacZ vector (40). The human retina cells 911 (41)
were co-transfected with 3 g of pAd-CMV-PrP HG Sal DNA and 0.6 g
of the plasmid pSV2neo carrying a neomycin resistance gene (42).
Following calcium phosphate transfection, cells were split into three
dishes and cultured in the presence of 0.9 mg/ml neomycin. After 3
weeks of selection, about 40–80 clones/plate were obtained in each
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transfection. Three bulk cultures for each construct were analyzed for
PrP expression by flow cytometry. CPs2 cells were derived from a single
cloned cell that was selected for high PrP expression using fluorescence-
activated cell sorting with the polyclonal antibody 1B3 against mouse
PrP (43) and a phycoerythrin-conjugated secondary antibody.
Metabolic Pulse-Chase Radiolabeling—Splenocyte cell suspensions
were prepared from spleens of various mouse strains and used at 1–3 
107 splenocytes/sample. Cerebellar granule cells were used at 106 cells/
labeling experiment. Prior to labeling, cells were washed once with
phosphate-buffered saline and starved for 30 min to 1 h at 37 °C in
methionine/cysteine-free Dulbecco’s modified Eagle’s medium (Sigma)
supplemented with 10% dialyzed fetal bovine serum (Sigma), 2 mM
L-glutamine (Life Technologies), 2 mM L-cysteine (Life Technologies),
and 10 mM Hepes buffer (pH 7.4) (Sigma). This medium was then
replaced with 1 mCi of Tran[35S]methionine (ICN Biomedicals)/ml in
methionine-free Dulbecco’s modified Eagle’s medium containing the
supplements described above for varied metabolic labeling times. At the
end of the labeling period, cells were either washed once with cold
phosphate-buffered saline, lysed, and processed for immunoprecipita-
tion as described below or chased with cell culture medium (Dulbecco’s
modified Eagle’s medium or RPMI) containing all of the supplements
for the appropriate length of time. At different time points of the chase
period, cells and medium were harvested and separated by centrifuga-
tion at 800  g for 4 min.
Cell Lysis and Tissue Homogenates—Cells were lysed in lysis buffer
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA (TNE), 0.5%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1 mM phenylmethylsulfonyl
fluoride, on ice for 5 min. The insoluble material was removed by
centrifugation at 4000  g for 10 min, and Sarkosyl was added to 0.4%.
Tissue homogenates (10%, w/v) of various mouse organs were pre-
pared either in TNE (for brain) or phosphate-buffered saline (for
spleen), both containing 2% Sarkosyl and 1 mM phenylmethylsulfonyl
fluoride, by using an electric homogenizer (Polytron; Kinematica). The
homogenates were cleared from insoluble material by centrifugation at
12,000–15,000  g for 15 min.
Immunoprecipitation—To reduce nonspecific binding, radiolabeled
proteins (500-l aliquots of cell lysates or medium) were first preabsorbed
with 20 l of Gamma-Bind-Plus Sepharose (Amersham Pharmacia Bio-
tech) for 1 h at 4 °C. Sepharose beads were centrifuged at 13,000  g for
1 min, and the supernatant was used for immunoprecipitation.
For detection of PrP, polyclonal anti-PrP antibody R340 (20 g) was
added to the medium or lysate, and, after overnight incubation at 4 °C,
the protein-antibody complexes were absorbed to Gamma-Bind-Plus
Sepharose (40 l/500 l of solubilized protein) for 2 h at 4 °C. After
centrifugation at 13,000  g for 1 min, Sepharose-absorbed proteins
were washed twice with lysis buffer containing 0.4% Sarcosyl, followed
by two wash steps in high salt buffer (50 mM Tris-HCl, pH 7.5, 500 mM
NaCl, 0.1% Nonidet P-40, 0.05% sodium deoxycholate) and one wash
step in low salt buffer (50 mM Tris-HCl, pH 7.5, 0.1% Nonidet P-40,
0.05% sodium deoxycholate). All wash steps were performed at room
temperature for 10 min each using a roller shaker. The Sepharose was
resuspended in 3 loading buffer (1 loading buffer: 50 mM Tris-HCl,
pH 6.8, 2% SDS, 0.1% bromphenol blue, 10% glycerol), boiled for 4–5
min, and analyzed by 12% SDS-PAGE (44).
For the immunoprecipitation of PrP from mouse and human plasma,
the monoclonal antibody 6H4 (45) was first coupled to cyanogen bro-
mide-activated Sepharose 4B (Amersham Pharmacia Biotech). The cou-
pling procedure for 6H4 to cyanogen bromide-activated Sepharose and
the preparation of Tris-inactivated Sepharose, used as a negative con-
trol and for preabsorption, were performed as described in the manual
except that only 2 mg of 6H4 antibody/ml of gel were used for coupling.
The immunoprecipitation was carried out as described above for the
R340 antibody except for the following modifications. Preabsorption
was performed with 40 l of Tris-inactivated cyanogen bromide-acti-
vated Sepharose, and for the detection of PrP, 80 l (20 ng) of 6H4-
Sepharose were used.
Detection of Proteins by Autoradiography—After SDS-PAGE, pro-
teins were fixed, and the gel was incubated with fluorographic reagent
(Amplify from Amersham Pharmacia Biotech) and dried according to
the manual provided by the company. The gel was exposed to an x-ray
film, or the autoradiographic signals were quantitated by densitometric
analysis using phosphorimaging (Fujix Bas 2000). The amount of cel-
lular and soluble PrP present at a time point during chase incubations
is expressed as a percentage of the quantity of the nascent PrP recov-
ered at the end of the pulse-labeling period.
Separation of Blood—Heparinized mouse blood (1 ml) was taken by
heart puncture and centrifuged twice at 2,000  g for 10 min followed by
14,000  g for 10 min. Supernatant (serum) was collected after each
centrifugation step and finally analyzed by immunoprecipitation and
Western blotting.
Heparinized human peripheral blood (6 ml) was collected and sepa-
rated with Lympholyte-H (Cedarlane Laboratories) density gradient
centrifugation. The separation was performed according to the instruc-
tions provided by the manufacturer.
Analysis of PrPC Hydrophobicity Using Triton X-114 Phase Partition-
ing—A working stock solution of Triton X-114 was prepared as de-
scribed by Borchelt et al. (12); a 3% aqueous solution of Triton X-114
was mixed at 4 °C to solubilize the detergent. During an overnight
incubation at 37 °C, the solution separated into a large aqueous phase
and a smaller detergent phase. The aqueous phase was discarded, and
the detergent phase was mixed with 0.1 volume of 10 TNE to give the
Triton X-114 working stock.
To examine the hydrophobic properties of cellular proteins, cells were
lysed in TNE containing 0.25 volumes of Triton X-114 stock. The pro-
teins in medium were analyzed by first adding 0.1 volume of 10 TNE
and then 0.25 volume of Triton X-114 stock. All samples were cooled to
4 °C and centrifuged at 3000  g for 10 min at 4 °C to remove any
insoluble aggregates. The supernatant was heated to 37 °C to induce
phase transition and then centrifuged at 3000 g for 10 min. The upper
aqueous phase was transferred into a new tube, again mixed with 0.25
volume of Triton X-114 at 4 °C, and then heated to induce phase
transition. The partitioning of the aqueous phase was repeated two
more times to produce four separate detergent phases and one single
aqueous phase. Proteins of each phase were precipitated with 5 volumes
of methanol before immunopurification.
RESULTS
In wild-type mice, the highest concentration of PrPC was
found in the nervous system (Fig. 1, lane 1), whereas expres-
sion in wild-type spleen was barely detectable by immunoblot
analysis (Fig. 1, lanes 4 and 7). Tga20 transgenic mice express
at least 10 times more PrPC in the spleen than wild-type mice
(Fig. 1, lane 5) due to a high copy number of a PrP transgene
(20). Expression of PrPC in Tg94/IRF mice is driven by the
interferon regulatory factor-1 promoter and the E enhancer,
which results in 1000-fold higher levels of PrPC in the spleen
(Fig. 1, lane 6) compared with wild-type mice (19). Surpris-
ingly, the PrP glycosylation pattern of Tg94/IRF splenocytes
differs from the pattern found in tga20 transgenic mice. Most
likely, this reflects cell-specific glycosylation, indicating that
different cell populations express PrP in these transgenic mice
(19).
Turnover of PrPC in Primary Splenocyte Cultures of Tg94/
IRF Mice—We used metabolic pulse-chase radiolabeling exper-
iments to examine the biosynthesis and degradation of PrPC in
the lymphoreticular system. Initial attempts to metabolically
radiolabel PrP in splenocytes prepared from wild-type mice
failed due to the low expression level of PrP in wild-type spleen
(data not shown). We then used primary cultures derived from
spleens of Tg94/IRF mice, which overexpress about 1000-fold
more PrP in the spleen than wild-type mice (19). PrP was
pulse-labeled with [35S]methionine for 3 h followed by a chase
period of up to 17 h in complete medium supplemented with an
excess of unlabeled methionine. The radiolabeled PrP was then
immunoprecipitated with polyclonal antibody R340 (21) and
analyzed by SDS-PAGE and fluorography. The autoradiograph
FIG. 1. Expression levels of PrPC in tissues of wild-type and
transgenic mice. Aliquots (25 g of total protein) of brain or spleen
homogenates were loaded in each lane. PrP was detected on blots with
1:5000 diluted polyclonal anti-PrP antiserum 1B3 (43). Lane 1, wild-
type (Prnp/) brain; lane 2, Prnp0/0 brain; lane 3, Prnp0/0 spleen; lane
4, Prnp/ spleen; lane 5, tga20 spleen; lane 6, Tg94/IRF spleen; lane 7,
Prnp/ spleen (175 g of total protein). The positions of molecular
mass markers in kDa are designated on the left.
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shown in Fig. 2 as well as that from a similar experiment was
analyzed by phosphorimaging, and the signals for the various
glycosylated PrP isoforms were plotted as the fraction of the
signal observed at the end of the pulse period. The two sets of
data points show a great degree of reproducibility and can be fit
by a line for exponential decay using nonlinear regression
analysis. This analysis revealed a half-life for the newly syn-
thesized PrP in Tg94/IRF splenocytes of 1.5 h (Fig. 2). These
results indicate a faster degradation of cellular PrP in Tg94/
IRF splenocytes compared with the N2a neuronal cell line in
which PrP is degraded with a half-time of 3–6 h (9, 10).
Turnover of PrPC in Primary Splenocyte Cultures of tga20
Mice—Since PrP expression in Tg94/IRF splenocytes is driven
by a heterologous promoter, which results in at least 1000-fold
higher levels of PrPC in the spleen compared with wild-type
mice, we asked whether the biosynthesis and degradation of
PrPC had been influenced by the IRF-1 promoter or by the
strong overexpression of PrPC. Therefore, we performed similar
experiments with splenocytes from tga20 transgenic mice.
tga20 mice harbor multiple copies of a PrP transgene contain-
ing the native promoter and express 10-fold more PrPC in the
spleen than wild-type mice (Fig. 1). Following a 3-h pulse with
[35S]methionine, PrPC in tga20 splenocytes disappeared with a
half-time of 1.8 h (Fig. 3). These results confirm that turnover
of PrP in splenocytes is significantly faster than what was
reported for neuronal tumor cell lines. To exclude the possibil-
ity that overexpression of PrP results in an increased turnover
of PrP, we studied PrP degradation in CPs2 cells, a human
retina cell line, which overexpress murine PrP at a similar level
as Tg94/IRF splenocytes. However, radiolabeling studies in
CPs2 cells showed that PrP was degraded with a half-time of
5–6 h (data not shown), which is similar to the findings of PrP
degradation in neuroblastoma cells.
PrPC Turnover in Cerebellar Granule Cells—We next asked
whether the fast turnover of cell-associated PrP is specific for
lymphoid cells. If this were the case, it might explain why
prions multiply more efficiently in lymphoid tissues than in
nervous tissues. To that purpose, we investigated the metabo-
lism of PrPC in nontumorigenic cells of the nervous system. We
prepared primary cultures of cerebellar granule cells (CGC)
from tga20 transgenic mice. CGC were radiolabeled with
[35S]methionine for 3 h and chased up to 19 h (Fig. 4). Immu-
noprecipitation of radiolabeled PrPC and quantitation by phos-
phorimaging revealed a half-life of 1.8 h for cell-associated PrP,
which is similar to the kinetics for PrP disappearance in
splenocytes. Therefore, we conclude that PrPC is metabolized
with similar kinetics in both lymphoid and nervous tissue but
is more efficiently turned over in primary cells than in immor-
talized cell lines.
Release of PrPC from Primary Lymphoid and Neuronal
Cells—The mature form of PrP is attached to the cell surface by
a glycolipid. In neuronal cell lines as well as in hamster brain,
it has been shown that a form of PrP that lacks the GPI anchor
is shed into the extracellular space (10, 12, 13). Furthermore, a
soluble, N-terminally truncated form of PrP is released from
human platelets. Interestingly, this processed soluble form of
PrP that starts at Gly90 showed an electrophoretic mobility on
SDS-PAGE similar to PrP27–30, the protease-resistant core of
PrPSc (15). Using a time-resolved fluoroimmunoassay, MacGre-
gor et al. (22) showed that soluble forms of PrP are present in
various human blood fractions. It is still unclear whether sol-
uble PrP can be converted into PrPSc.
We examined the kinetics of the appearance of soluble forms
of PrP released from metabolically radiolabeled Tg94/IRF
splenocytes. Radiolabeled PrP was recovered from the medium
after various chase time points by immunoprecipitation. La-
beled PrPC was first detected at 1 h of chase period, and
maximal levels were present in the medium at 6 h. About 75%
of the total labeled PrPC was found to be accumulated in the
medium at the end of the chase time (Fig. 5). The same analysis
FIG. 2. Degradation of PrPC in splenocytes derived from Tg94/
IRF transgenic mice. 2  107 splenocytes were metabolically radio-
labeled for 3 h with [35S]methionine and then chased in complete
medium for increasing periods of time. Cells were harvested at the
indicated chase time, and cell lysates were used for immunoprecipita-
tion with the anti-PrP serum R340. PrP was visualized by SDS-PAGE
and fluorography. The first lane to the left is a negative control of
Prnp0/0 splenocytes lysed and immunoprecipitated at the end of the
pulse. The position of molecular mass markers are designated in kDa on
the left. Data from two experiments were quantitated by phosphorim-
ager analysis, and the values were plotted as a function of the chase
period. The values for PrPC are expressed as a percentage of the signal
detected at the end of the pulse labeling period. The data points were
fitted to an exponential curve using nonlinear regression analysis.
FIG. 3. Degradation of PrPC in splenocytes derived from tga20
transgenic mice. 2  107 splenocytes were metabolically radiolabeled
for 3 h with [35S]methionine and then chased in complete medium for
increasing periods of time. Cells were harvested at the indicated chase
time, and cell lysates were used for immunoprecipitation with the
anti-PrP serum R340. PrP was visualized by SDS-PAGE and fluorog-
raphy. The first lane to the left is a negative control of Prnp0/0 spleno-
cytes lysed and immunoprecipitated at the end of the pulse. The posi-
tion of molecular mass markers are designated in kDa on the left. Data
from two experiments were quantitated and analyzed as described in
Fig. 2.
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was performed with splenocytes (Fig. 6) and CGC (Fig. 7) of
tga20 mice. Immunoprecipitation of labeled PrPC from the me-
dium showed that PrPC is shed into the medium reaching a
maximal level of 56 and 91%, respectively, of the total labeled
cell-associated PrPC present at the end of the pulse period.
Interestingly, PrPC shed from tga20 splenocytes migrated pre-
dominantly as a single band around 35 kDa, corresponding to
the diglycosylated form, and the low molecular weight species
of PrPC found associated with the cells was almost completely
absent in the medium. The low molecular weight form may
FIG. 4. Degradation of PrPC in cerebellar granule cells derived
from tga20 transgenic mice. 106 cerebellar granule neurons were
metabolically radiolabeled for 3 h with [35S]methionine and then chased
in complete medium for increasing periods of time. Cells were harvested
and lysed at the indicated chase time, and 1 ml (of 1.5 ml) of cell lysate
was used for immunoprecipitation with the anti-PrP serum R340. PrP
was visualized by SDS-PAGE and fluorography. The positions of mo-
lecular mass markers are designated in kDa on the left. Data from one
experiment were quantitated and analyzed as described in the legend to
Fig. 2.
FIG. 5. Release of PrPC from splenocytes derived from Tg94/
IRF transgenic mice. 2  107 splenocytes were metabolically radio-
labeled for 3 h with [35S]methionine and then chased in complete
medium for increasing periods of time. One-third of the medium was
harvested at the indicated chase time and PrP immunoprecipitated
with the anti-PrP serum R340. PrP was visualized by SDS-PAGE and
fluorography. The position of molecular mass markers are designated in
kDa on the left. Data from two experiments were quantitated and
analyzed as described in the legend to Fig. 2.
FIG. 6. Release of PrPC from splenocytes derived from tga20
transgenic mice. 2  107 splenocytes were metabolically radiolabeled
for 3 h with [35S]methionine and then chased in complete medium for
increasing periods of time. One-third of the medium was harvested at
the indicated chase time, and PrP was immunoprecipitated with the
anti-PrP serum R340. PrP was visualized by SDS-PAGE and fluorog-
raphy. The positions of molecular mass markers are designated in kDa
on the left. Data from two experiments were quantitated and analyzed
as described in Fig. 2.
FIG. 7. Release of PrPC from cerebellar granule neurons de-
rived from tga20 transgenic mice. 106 cerebellar granule neurons
were metabolically radiolabeled for 3 h with [35S]methionine and then
chased in complete medium for increasing periods of time. Medium
was collected at the indicated chase time, and 1 ml (of 1.5 ml) of
medium was used for immunoprecipitation with the anti-PrP serum
R340. PrP was visualized by SDS-PAGE and fluorography. The
positions of molecular mass markers are designated in kDa on the
left. Data from two experiments were quantitated and analyzed as
described in the legend to Fig. 2.
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represent incompletely processed PrP molecules that are re-
tained in the cell and cannot be released.
Soluble PrP in Blood of Mice and Humans—Detection of
soluble PrPC in the culture medium of splenocytes suggested
that shedding of PrPC is part of a processing pathway in the
lymphoid system leading to the accumulation of significant
levels of soluble PrP in the blood (22). To verify the presence of
soluble PrPC in serum, we examined mouse and human blood.
Serum of Tg94/IRF mice was obtained by centrifugation of
whole blood to remove white blood cells and erythrocytes. PrPC
was immunoprecipitated from the serum with the monoclonal
antibody 6H4. Western blot analysis of the immunoprecipitates
revealed a faint PrP band in the Tg94/IRF plasma, whereas
control immunoprecipitates from Prnp0/0 serum showed no
corresponding signal (Fig. 8). Similarly, PrP was immunopre-
cipitated from human serum using 6H4-Sepharose and showed
on immunoblots an array of bands around 35 kDa (Fig. 8).
Control immunoprecipitations with Sepharose alone did not
show any bands on the Western blot. PNGase F treatment of
serum PrP resulted in a single band of 28 kDa representing the
unglycosylated form of PrP, demonstrating that the heteroge-
neity of the PrP bands is due to various degrees of N-linked
glycosylation (data not shown) (23–25). The fact that substan-
tial amounts of soluble PrP were found in plasma of mice and
humans suggests that shed PrP might be of physiological
relevance.
It has been shown that shed PrP from primary cultures of
neonatal hamster brain lacks the GPI anchor (12). Whether
PrP shedding in the lymphoreticular system involves a similar
processing event is still elusive. To determine whether release
of PrP from lymphoid cells involves removal of the glycolipid
moiety, we carried out Triton X-114 phase partitioning (26) of
radiolabeled PrPC from splenocytes and conditioned medium.
We found that the majority of the cell-associated PrP parti-
tioned into the detergent phase (D1/2; Fig. 9), characteristic of
the GPI-modified protein. In contrast, most of the soluble PrP
in the medium partitioned in the aqueous phase (A, Fig. 9),
indicating that these PrP molecules lack the GPI anchor. We
conclude that most of the PrP molecules released from spleno-
cytes have lost their GPI moiety, suggesting that membrane-
anchored PrP is processed to yield nonanchored, hydrophilic
forms of PrP that are released into the medium.
DISCUSSION
In the present study, we have investigated the metabolism of
PrPC in primary cells derived from lymphoid tissue and com-
pared it with the turnover of PrPC in nervous tissue. Since
PrPC is the precursor in the conversion of PrPC into the patho-
logic isoform PrPSc, the kinetics of PrPC metabolism could hold
important clues with regard to the efficiency of PrPSc and prion
synthesis in different tissues.
PrPC metabolism was studied in primary splenic cultures of
two different transgenic mice, tga20 and Tg94/IRF, which over-
express PrPC in the spleen about 10- and 1000-fold, respec-
tively, compared with wild-type mice (19, 20). In both trans-
genic mice, the half-life for the disappearance of PrP in
splenocytes was found to be 1.5–2 h. The finding that PrPC
turnover is faster in splenocytes than in immortalized neuronal
cells suggested that the processing and possibly also the con-
version of PrPC into PrPSc could be faster in lymphoid tissues.
We therefore examined the kinetics of PrPC metabolism in
primary cerebellar granule cell cultures. Our results showed
that, similarly to splenocytes, primary neuronal cells showed a
half-time for PrPC degradation of 1.5–2 h. Since PrPC turnover
in splenocytes is similar to the turnover in granule cells, turn-
over of PrPC seemed not to be responsible for the fast replica-
tion of prions in the lymphoid system. However, it is also
possible that turnover of PrP in splenocyte cultures mainly
reflects turnover of PrP in lymphocytes, which may not be
relevant for prion replication, but these constitute more than
90% of the cells in splenocyte cultures (27). It has been shown
that neither T (19) nor B cells (28) are capable of prion repli-
cation. On the other hand, FDCs that have been incriminated
to play a crucial role in prion replication (5, 29–31) constitute
less than 1% of the cells in secondary lymphoid organs and are
known to be difficult to isolate in an intact form (27).
The fast degradation of PrP in primary tissues is in contrast
to studies of PrP metabolism in cultured neuroblastoma cells,
where PrP is degraded with a half-time of 3–6 h (9, 10). It is
possible that the overexpression of PrP could be responsible for
this discrepancy. However, we found that PrP in human retina
CPs2 cells that overexpress mouse PrP at a similar level as
Tg94/IRF splenocytes was degraded with a half-time of 5–6 h
as reported for mouse neuroblastoma cells. These results sug-
gest that overexpression of PrP is not responsible for the fast
degradation rate of PrP in primary tissues. Furthermore, these
findings support the notion that PrPC is degraded faster in
primary cells than in the cell lines that were reported before (9,
10).
Earlier studies showed that several GPI-anchored glycopro-
teins are shed from the cell membrane and exist as soluble
FIG. 8. Detection of soluble PrP in serum of humans and trans-
genic Tg94/IRF mice. Serum was separated from peripheral blood
cells by centrifugation, and PrP was immunoprecipitated with the
monoclonal anti-PrP antibody 6H4 covalently linked to Sepharose ().
As a negative control, some samples were treated with unconjugated
Sepharose (). Aliquots (20 g of total protein) of wild-type (Prnp/)
or PrP knockout (Prnp0/0) mouse brain homogenates were directly
loaded onto the gel as controls. Following SDS-PAGE, PrP was visual-
ized by Western blot analysis using the polyclonal anti-PrP serum 1B3.
The positions of molecular mass markers are indicated in kDa on the
left.
FIG. 9. Shed PrP from splenocytes lacks the glycolipid anchor.
tga20 splenocytes were metabolically radiolabeled for 3 h with [35S]me-
thionine (cells) followed by a chase period of 4–24 h (medium). Cells
(2  107) and medium (from 4  107 cells) were extracted in Triton
X-114 and partitioned to examine the Triton X-114 partitioning prop-
erties of cell-associated and soluble PrP. Protein from the aqueous (A)
and the three subsequent Triton X-114 detergent phases (D1/2, D3, and
D4) were concentrated by methanol precipitation before immunopuri-
fication with the polyclonal anti-PrP serum R340, and PrP was visual-
ized by SDS-PAGE and fluorography. The positions of molecular mass
markers are designated in kDa.
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proteins in vitro and in vivo (32, 33). In addition, there is
evidence for a soluble form of PrPC in the medium of cultured
cells (9–13), in human cerebrospinal fluid (14), in human blood
(22), and released from activated human platelets (15).
To investigate whether shedding of PrP is a physiologically
relevant processing pathway for PrP, we metabolically labeled
splenocytes of Tg94/IRF and tga20 transgenic mice and fol-
lowed the release of a soluble form of PrPC into the medium. A
soluble form appeared as early as 2 h after starting the chase
period and was present at a level corresponding to 60–70% of
the labeled cellular PrPC, which is in stark contrast to earlier
findings in neuroblastoma cells, where only 10–30% of the
cellular PrPC was shed into the medium (9–13). Since in some
of these studies serum was omitted from the chase medium, the
high levels of shed PrP were possibly due to the presence of
serum in the chase medium. We carried out radiolabeling ex-
periments in CPs2 cells and performed chase incubations with
or without serum. Without serum, about 5% of the total labeled
PrP was shed after 17 h of chase, whereas about 15% of the
total labeled PrP was released into the medium with serum
(data not shown). These results suggest that serum enzymes
such as phosphatidylinositol-specific phospholipase C or D
might be involved in the release of PrP from cells. A number of
GPI-anchored proteins on lymphocytes have been shown to be
released by phospholipases in the serum and to exert important
signaling functions in the lymphoid system (34). Whether sol-
uble PrP has such a function remains to be seen.
Our finding that substantial amounts of shed PrP are pres-
ent in serum of mice and humans raises the question of
whether soluble PrP can be converted into PrPSc. Although
firm evidence for the presence of prion infectivity in blood is
still missing, it was recently shown that blood from bovine
spongiform encephalopathy-infected cattle can transmit the
disease to sheep (35). This scenario has far reaching conse-
quences for public health, because it would suggest that blood
donors subclinically infected with the bovine spongiform en-
cephalopathy agent could potentially transmit variant
Creutzfeldt-Jakob disease via blood transfusion to healthy in-
dividuals. This stresses the urgent need to develop sensitive
tests for the detection of prions in body fluids. Several recent
reports raise hope that this should be accomplished in the not
too distant future. An erythroid-specific transcript, erythroid
differentiation-related factor, was shown to be down-regulated
in the blood of scrapie-infected sheep (36). This might represent
a valuable diagnostic marker to screen the blood supply. Im-
proved diagnostic tests could now be developed using a new
cyclic amplification procedure, which is capable of efficiently
amplifying minute amounts of PrPSc in brain tissue (37). Cou-
pled with a reagent that specifically binds to PrPSc, such as the
recently identified plasminogen (38), this might reveal the lev-
els of prion infectivity looming in the blood.
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